Who are LENALIDOMIDE's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): POMALIDOMIDE, Pomalyst, Revlimid.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chembl-chembl848.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

LENALIDOMIDE — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LENALIDOMIDE (LENALIDOMIDE) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thalidomide Analog [EPC].

marketed Thalidomide Analog [EPC] Small molecule Live · refreshed every 30 min

Target snapshot

LENALIDOMIDE (LENALIDOMIDE).

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
LENALIDOMIDE TARGET	LENALIDOMIDE		marketed	Thalidomide Analog [EPC]		2005-01-01
POMALIDOMIDE	POMALIDOMIDE		marketed	Thalidomide Analog [EPC]		2013-01-01
Pomalyst	pomalidomide	Bristol-Myers Squibb	marketed	Thalidomide Analog [EPC]	Protein cereblon	2013-01-01
Revlimid	lenalidomide	Bristol-Myers Squibb	marketed	Thalidomide analogue	Cereblon (component of cullin ring E3 ubiquitin ligase enzyme complex)	2005-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thalidomide Analog [EPC] class)

· 2 drugs in this class
Bristol-Myers Squibb · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LENALIDOMIDE — Competitive Intelligence Brief. https://druglandscape.com/ci/chembl-chembl848. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing